Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial
Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care and improvements were maintained at 26 weeks.
Background: Hot flushes and night sweats affect 65‑85% of women after breast cancer treatment, causing distress and reducing quality of life. Hormone replacement therapy is often contraindicated. Non‑hormonal treatments are needed. This randomized controlled trial evaluated the effectiveness of group cognitive behavioural therapy (CBT) for managing HFNS in breast cancer survivors. Methods: 96 women with problematic HFNS after completion of breast cancer treatment were randomized to usual care or usual care plus group CBT (six weekly 90‑minute sessions). The primary outcome was HFNS problem rating at 9 weeks; secondary outcomes included HFNS rating at 26 weeks and quality‑of‑life measures. Results: At 9 weeks, the CBT group showed a mean difference of −1.77 (95% CI −2.43 to −1.91; p<0.0001) in HFNS problem rating compared to usual care, and the benefit persisted at 26 weeks (mean difference −1.76; 95% CI −2.54 to −1.99; p<0.0001). No CBT‑related adverse events were reported. Interpretation: Group CBT is a safe and effective non‑hormonal treatment for hot flushes and night sweats in breast cancer survivors, with additional benefits for mood, sleep, and quality of life.
Managing hot flushes and night sweats improves quality of life and may increase adherence to adjuvant endocrine therapy. A non‑hormonal, psychotherapy‑based approach is safe and tolerable for breast cancer survivors.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC